Sign in to view content

Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes with Nonexudative AMD Trial (PREVENT): A Prospective Controlled

Maziar Lalezary, MD, FASRS

Video
Published 2018

Related

Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial
Carl J Danzig, MD
Annual Meeting Talks
2020
Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more